Clinical consequences of upfront pathology review in the randomised PORTEC-3 trial for high-risk endometrial cancer
SM de Boer, BG Wortman, T Bosse, ME Powell, N Singh, H Hollema, G Wilson, MN Chowdhury, L Mileshkin, J Pyman, D Katsaros, S Carinelli, A Fyles, CM McLachlin, C Haie-Meder, P Duvillard, RA Nout, KW Verhoeven-Adema, H Putter, CL Creutzberg Show all
Annals of Oncology | OXFORD UNIV PRESS | Published : 2018
Awarded by Dutch Cancer Society, The Netherlands
Awarded by Cancer Research UK
This work was supported by a grant from the Dutch Cancer Society (UL2006-4168/CKTO 2006-04), The Netherlands. The PORTEC-3 trial was supported in the UK by Cancer Research UK (C7925/A8659). This study is registered with ISRCTN (ISRCTN14387080, www.controlled-trials.com) and with ClinicalTrials.gov (NCT00 411138). The travel and stay in the UK for this project has been sponsored by the Leiden University Fund/van Steeden.